The diagnosis and management of allergic reactions in patients sensitized to non‐specific lipid transfer proteins

Sensitization to one or more non‐specific lipid transfer proteins (nsLTPs), initially thought to exist mainly in southern Europe, is becoming accepted as a cause of allergic reactions to plant foods across Europe and beyond. The peach nsLTP allergen Pru p 3 is a dominant sensitizing allergen and pea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergy (Copenhagen) 2021-08, Vol.76 (8), p.2433-2446
Hauptverfasser: Skypala, Isabel J., Bartra, Joan, Ebo, Didier G., Antje Faber, Margaretha, Fernández‐Rivas, Montserrat, Gomez, Francisca, Luengo, Olga, Till, Stephen J., Asero, Riccardo, Barber, Domingo, Cecchi, Lorenzo, Diaz Perales, Araceli, Hoffmann‐Sommergruber, Karin, Anna Pastorello, Elide, Swoboda, Ines, Konstantinopoulos, Anastasios. P., Ree, Ronald, Scala, Enrico
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sensitization to one or more non‐specific lipid transfer proteins (nsLTPs), initially thought to exist mainly in southern Europe, is becoming accepted as a cause of allergic reactions to plant foods across Europe and beyond. The peach nsLTP allergen Pru p 3 is a dominant sensitizing allergen and peaches a common food trigger, although multiple foods can be involved. A frequent feature of reactions is the requirement for a cofactor (exercise, alcohol, non‐steroidal anti‐inflammatory drugs, Cannabis sativa) to be present for a food to elicit a reaction. The variability in the food and cofactor triggers makes it essential to include an allergy‐focused diet and clinical history in the diagnostic workup. Testing on suspected food triggers should also establish whether sensitization to nsLTP is present, using purified or recombinant nsLTP allergens such as Pru p 3. The avoidance of known trigger foods and advice on cofactors is currently the main management for this condition. Studies on immunotherapy are promising, but it is unknown whether such treatments will be useful in populations where Pru p 3 is not the primary sensitizing allergen. Future research should focus on the mechanisms of cofactors, improving diagnostic accuracy and establishing the efficacy of immunotherapy.
ISSN:0105-4538
1398-9995
DOI:10.1111/all.14797